RVMD

Revolution Medicines Inc

190.74

Sep 23 • 3:59 PM ET -2.12 (-1.10%)

190.73

Aftermarket • 7:57 PM ET -0.01 (-0.01%)

Healthcare Biotechnology USA Large NASD

Peers: ARGX REGN ONC VRTX ALNY BMRN BIIB AAPG AMGN GILD

| Held by: VTI VB VBK VXF IBB IWP IWR XBI IWF VHT

Scroll to Statements

Index	-
Market Cap	40.88B
Enterprise Value	38.14B
Income	-1.77B
Sales	0.00M
Book/sh	12.16
Cash/sh	18.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	883
IPO	Feb 13, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	15.68
P/C	10.38
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.38
Current Ratio	11.38
Debt/Eq	0.46
LT Debt/Eq	0.45
Option/Short	Yes / Yes

EPS (ttm)	-8.81
EPS next Y	-5.93
EPS next Q	-2.40
EPS this Y	-62.57%
EPS next Y	38.73%
EPS next 5Y	23.90%
EPS past 3/5Y	-24.48% -29.13%
Sales past 3/5Y	- -
EPS Y/Y TTM	-95.67%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-132.54%
Sales Q/Q	-
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-49.81% -100.00%

Insider Own	9.95%
Insider Trans	-3.07%
Inst Own	92.45%
Inst Trans	6.44%
ROA	-52.37%
ROE	-79.09%
ROIC	-46.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.55%
SMA50	-4.40%
SMA200	34.76%
Trades

Shs Outstand	214.24M
Shs Float	193.01M
Short Float	5.04%
Short Ratio	4.41
Short Interest	9.73M
52W High	224.31 -14.97%
52W Low	42.18 352.20%
Volatility	3.38% 3.95%
ATR (14)	7.40
RSI (14)	36.52
Beta	1.40
Rel Volume	0.96
Avg Volume	2.20M
Volume	2,124,868

Perf Week	-2.64%
Perf Month	-9.85%
Perf Quarter	12.35%
Perf Half Y	99.69%
Perf YTD	139.47%
Perf Year	331.49%
Perf 3Y	535.80%
Perf 5Y	497.56%
Perf 10Y	-
Recom	1.09
Target Price	253.30
Prev Close	192.86
Price	190.74
Change %	-1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-26	Initiated	Morgan Stanley	Overweight	$255
May-22-26	Initiated	Bernstein	Mkt Perform	$151
May-18-26	Resumed	Truist	Buy	$179
Mar-16-26	Resumed	Jefferies	Buy
Feb-27-26	Resumed	UBS	Buy	$145
Nov-18-25	Initiated	Wolfe Research	Outperform	$75
Nov-03-25	Initiated	RBC Capital Mkts	Outperform	$77
Oct-21-25	Initiated	Mizuho	Outperform	$90
Oct-16-25	Resumed	Stifel	Buy	$85
Sep-12-25	Resumed	Raymond James	Strong Buy	$72
Sep-05-25	Initiated	Truist	Buy	$99
Aug-19-25	Initiated	Piper Sandler	Overweight	$75
Aug-15-25	Initiated	Wells Fargo	Overweight	$67
Jul-15-25	Initiated	Goldman	Buy	$65
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43

Show Previous Ratings

Sep-14-26 04:05PM	Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer (GlobeNewswire)
Sep-10-26 01:14PM	'Miracle' Cancer Drug Sets Revolution Medicines Up for More Market Gains (Barrons.com)
Sep-04-26 05:00AM	Ionis rare neurology drug approved; Pfizer inks an ADC deal (BioPharma Dive)
Sep-02-26 05:50PM	New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Aug-28-26 10:13AM	New pancreatic cancer drug carries a $39,800 monthly list price: What to know (Yahoo Personal Finance) -6.00%
09:21PM	Loading…
Aug-27-26 09:21PM	Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent (The Wall Street Journal)
02:54PM	Revolution Medicines $39,800-Monthly Cancer Drug Puts Access In Focus CEO Goldsmith Expects Insurers To Move Swiftly To Provide Coverage (Stocktwits)
07:37AM	3 Reasons the AI Stock Boom Is Very Much Back (Barrons.com)
Aug-26-26 06:33PM	Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet (Fortune)
06:22PM	Sellas Traders See Pancreatic Cancer Race After RVMDs Drug Approval But Near-Term Focus Remains On SLSs Leukemia Pipeline (Stocktwits)
04:33PM	Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution (PR Newswire)
03:52PM	RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill Is Drug Price Overshadowing Approval? (Stocktwits)
12:59PM	U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer (GlobeNewswire)
12:20PM	FDA Approves 'Unprecedented' Pancreatic Cancer Drug (Investor's Business Daily)
11:37AM	Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. (Barrons.com)
09:35AM	Loading…
09:35AM	Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA (BioPharma Dive)
Aug-24-26 05:42AM	3 potential blockbusters beyond obesity to watch (Pharma Voice)
Aug-11-26 06:12AM	BeOne and Revolution Medicines partner for oncology therapies (Pharmaceutical Business Review)
Aug-10-26 06:00AM	BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration (Business Wire)
Aug-07-26 06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
Aug-06-26 01:11AM	Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highlights: Daraxonrasib Poised to ... (GuruFocus.com)
Aug-05-26 04:02PM	Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-26 12:45PM	Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test (Investor's Business Daily)
Jul-29-26 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 (GlobeNewswire) +6.22%
Jul-24-26 07:30AM	Big pharmas patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it (Fortune)
05:00AM	Novo escalates legal fight with Lilly; J&J reinforces dominance in multiple myeloma (BioPharma Dive)
Jul-22-26 04:05PM	Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer (GlobeNewswire)
Jul-08-26 05:07AM	Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal (BioPharma Dive)
Jul-07-26 09:23AM	European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process (GlobeNewswire)
Jul-03-26 07:20AM	Revolutions RAS inhibitor pipeline posts more pancreatic cancer trial wins (Clinical Trials Arena)
08:00AM	Loading…
Jul-02-26 08:00AM	Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 (GlobeNewswire)
Jun-26-26 03:38PM	This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In. (Barrons.com)
07:53AM	FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services (BioPharma Dive)
Jun-24-26 07:31PM	Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 (GlobeNewswire)
Jun-23-26 08:00AM	Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer (GlobeNewswire)
Jun-22-26 08:00AM	Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. (GlobeNewswire)
Jun-09-26 09:32AM	Tango Therapeutics stock surges on pancreatic cancer drug combo data (Quartz)
09:31AM	Tango Therapeutics stock surges on pancreatic cancer trial data (Quartz)
Jun-08-26 04:09PM	Tango Skyrockets On Eye-Popping Pancreatic Cancer Results (Investor's Business Daily)
12:28PM	Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment (Barrons.com)
08:13AM	Tango data add to growing momentum for pancreatic cancer drugs (BioPharma Dive)
Jun-05-26 04:55AM	GSK, Takeda and others notch key clinical wins in tough-to-treat diseases (Pharma Voice)
Jun-01-26 10:26AM	Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case (GuruFocus.com)
May-31-26 09:01PM	RVMD Stock Jumps Overnight: New Drug Heads To FDA After Unprecedented 1-Year Survival Win In Pancreatic Cancer (Stocktwits)
08:06AM	Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer (GlobeNewswire)
May-22-26 07:46AM	ASCO26: 5 data snapshots ahead of the years biggest cancer drug meeting (BioPharma Dive)
May-21-26 04:05PM	Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation (GlobeNewswire)
May-07-26 08:30AM	Revolution Medicines, Inc. Q1 2026 Earnings Call Summary (Moby) -5.67%
May-06-26 06:00PM	Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer (GlobeNewswire)
04:02PM	Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire)
Apr-29-26 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026 (GlobeNewswire)
03:07PM	Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges (GuruFocus.com)
03:50AM	Revolutions on a pancreatic cancer winning streak. What comes next for the biotech? (Pharma Voice)
Apr-28-26 03:58PM	Erasca Shares Crater After Cancer Trial Update Reveals Patient Death (The Wall Street Journal) +9.99%
09:33AM	Erasca Plummets Despite 'Phenomenal' Results In Pancreatic Cancer (Investor's Business Daily)
05:30AM	There's a Revolution in Cancer. But Can Big Pharma Afford It? (The Wall Street Journal)
Apr-21-26 05:35PM	Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting (GlobeNewswire)
05:30PM	Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting (GlobeNewswire)
11:23AM	Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-20-26 06:43AM	AACR 2026: Revolutions next prospect, Mercks reveal and a lung cancer battle (BioPharma Dive)
Apr-19-26 02:00PM	Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting (GlobeNewswire)
Apr-17-26 04:02PM	Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-16-26 07:00AM	Replimune cuts staff; MeiraGTx reacquires eye gene therapy (BioPharma Dive)
Apr-15-26 12:41AM	Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes (GlobeNewswire)
Apr-13-26 04:01PM	Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes (GlobeNewswire) +41.35% +7.86%
11:09AM	Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial (CNBC TV)
10:34AM	How This Biotech Stock Skirted Today's Selloff (Schaeffer's Research)
09:11AM	This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success. (Barrons.com)
09:11AM	Revolution Medicines Catapults 30%-Plus On Upbeat Results For Pancreatic Cancer Drug (Investor's Business Daily)
08:00AM	Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer (GlobeNewswire)
07:46AM	Revolution pancreatic cancer drug nearly doubles survival in key trial (BioPharma Dive)
Apr-10-26 05:57PM	Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer (CNBC TV)
Apr-02-26 08:00AM	Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer (GlobeNewswire)
Mar-17-26 06:37PM	Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-26 04:10PM	Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact (Investor's Business Daily)
Mar-02-26 02:57AM	Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs (Insider Monkey)
Feb-26-26 11:53PM	Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating - Here's Why (Insider Monkey)
09:38AM	RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View (Zacks)
08:30AM	Revolution Medicines, Inc. Q4 2025 Earnings Call Summary (Moby)
08:04AM	Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment? (Insider Monkey)
02:11AM	Revolution Medicines Q4 Earnings Call Highlights (MarketBeat)
12:04AM	Revolution Medicines Inc (RVMD) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Feb-25-26 04:02PM	Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-24-26 04:05PM	Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
08:30AM	Summit Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
01:23AM	JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout (Insider Monkey)
Feb-18-26 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 (GlobeNewswire)
Feb-15-26 02:02PM	Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat (MarketBeat)
Feb-14-26 10:02PM	Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push (MarketBeat)
Feb-13-26 02:07PM	Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat (MarketBeat)
Feb-04-26 04:05PM	Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-29-26 08:00AM	Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor (GlobeNewswire)
Jan-27-26 10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
06:23AM	Stock Index Futures Gain on Tech Boost, FOMC Meeting and Earnings in Focus (Barchart)
05:02AM	Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan (Insider Monkey)
03:39AM	Stock Market Today: Nasdaq Futures Rise Ahead of Earnings; Yen Weakens (The Wall Street Journal)
Jan-26-26 07:36PM	Why Revolution Medicines Stock Plummeted by Almost 17% Today (Motley Fool) -16.87%
04:56PM	Stocks to Watch Monday Recap: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
04:32PM	Stocks Close Higher Ahead of Heavy Earnings Week and FOMC Meeting (Barchart)
01:48PM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Ph.D.Dr. Mark A. Goldsmith M.D.

Chief Financial OfficerMr. Jack Anders

Chief Operating OfficerMs. Margaret A. Horn J.D.

Senior VPMr. Jeffrey Cislini J.D.

FRCPDr. Stephen M. Kelsey FRC Path.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mancini Anthony	See Remarks	Sep 18 '26	Sale	196.94	1,764	347,402	40,352	Sep 22 06:00 PM
Elizabeth Anderson	Director	Sep 22 '26	Proposed Sale	192.76	15,080	2,906,821		Sep 22 04:13 PM
Sandler Alan B.	Chief Development Officer	Sep 16 '26	Sale	199.24	341	67,941	52,868	Sep 18 06:06 PM
Mancini Anthony	See Remarks	Sep 16 '26	Sale	199.24	1,774	353,449	42,116	Sep 18 06:05 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '26	Sale	199.24	5,569	1,109,554	286,307	Sep 18 06:04 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '26	Sale	199.24	4,967	989,613	149,680	Sep 18 06:03 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '26	Sale	199.24	13,988	2,786,938	253,342	Sep 18 06:02 PM
Cislini Jeff	SVP & General Counsel	Sep 16 '26	Sale	199.24	3,366	670,631	52,541	Sep 18 06:01 PM
Anders Jack	Chief Financial Officer	Sep 16 '26	Sale	199.24	4,053	807,513	119,216	Sep 18 06:00 PM
ANTHONY MANCINI	Officer	Sep 18 '26	Proposed Sale	196.94	1,764	347,402		Sep 18 04:18 PM
Sandler Alan B	Officer	Sep 15 '26	Proposed Sale	203.77	331	67,448		Sep 15 06:11 PM
Mancini Anthony	Officer	Sep 15 '26	Proposed Sale	203.77	2,377	484,361		Sep 15 06:10 PM
Kelsey Stephen Michael	Officer	Sep 15 '26	Proposed Sale	203.77	5,415	1,103,415		Sep 15 06:09 PM
Horn Margaret A	Officer	Sep 15 '26	Proposed Sale	203.77	4,830	984,209		Sep 15 06:08 PM
Goldsmith Mark A	Officer	Sep 15 '26	Proposed Sale	203.77	13,603	2,771,883		Sep 15 06:07 PM
Cislini Jeff	Officer	Sep 15 '26	Proposed Sale	203.77	3,272	666,735		Sep 15 06:06 PM
Anders Jack	Officer	Sep 15 '26	Proposed Sale	203.77	3,939	802,650		Sep 15 06:05 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '26	Option Exercise	41.71	92,531	3,859,488	384,407	Sep 15 06:00 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '26	Sale	202.36	92,531	18,724,767	291,876	Sep 15 06:00 PM
Mancini Anthony	See Remarks	Sep 10 '26	Option Exercise	33.62	9,363	314,784	59,338	Sep 14 06:03 PM
Mancini Anthony	See Remarks	Sep 10 '26	Sale	204.16	15,448	3,153,807	43,890	Sep 14 06:03 PM
STEPHEN KELSEY	Officer	Sep 11 '26	Proposed Sale	203.35	92,531	18,816,179		Sep 11 04:32 PM
Kim Lorence H.	Director	Sep 08 '26	Sale	209.82	17,090	3,585,837	0	Sep 10 05:52 PM
ANTHONY MANCINI	Officer	Sep 10 '26	Proposed Sale	207.68	15,448	3,208,241		Sep 10 04:39 PM
Kim Lorence H.	Director	Aug 31 '26	Sale	203.24	56,000	11,381,288	17,090	Sep 02 04:30 PM
Lorence H Kim	Affiliate	Aug 31 '26	Proposed Sale	207.88	73,090	15,193,949		Aug 31 05:11 PM
Cislini Jeff	General Counsel	Aug 21 '26	Option Exercise	20.00	56,280	1,125,687	112,801	Aug 25 04:06 PM
Cislini Jeff	General Counsel	Aug 21 '26	Sale	209.24	56,894	11,904,247	55,907	Aug 25 04:06 PM
GOLDSMITH MARK A	See Remarks	Aug 21 '26	Option Exercise	4.73	80,000	378,400	347,330	Aug 25 04:06 PM
GOLDSMITH MARK A	See Remarks	Aug 21 '26	Sale	209.20	80,000	16,735,887	267,330	Aug 25 04:06 PM
GOLDSMITH MARK A	See Remarks	Aug 21 '26	Sale	209.20	6,000	1,255,219	61,424	Aug 25 04:06 PM
THE JONATHAN GOLDSMITH REVOCAB	Director	Aug 21 '26	Proposed Sale	211.74	3,000	635,205		Aug 21 04:38 PM
THE REBECCA GOLDSMITH REVOCABL	Director	Aug 21 '26	Proposed Sale	211.74	3,000	635,205		Aug 21 04:38 PM
MARK A GOLDSMITH	Director	Aug 21 '26	Proposed Sale	211.74	80,000	16,938,800		Aug 21 04:37 PM
JEFFREY TODD CISLINI	Officer	Aug 21 '26	Proposed Sale	211.73	75,894	16,069,416		Aug 21 04:33 PM
Patel Sushil	Director	Jun 29 '26	Option Exercise	37.54	2,955	110,931	27,236	Jul 01 06:25 PM
Patel Sushil	Director	Jun 29 '26	Sale	187.99	5,580	1,048,967	21,656	Jul 01 06:25 PM
SUSHIL PATEL	Director	Jun 29 '26	Proposed Sale	182.08	5,580	1,016,006		Jun 29 04:44 PM
Anders Jack	Chief Financial Officer	Jun 24 '26	Option Exercise	18.56	20,000	371,200	143,269	Jun 26 04:10 PM
Anders Jack	Chief Financial Officer	Jun 24 '26	Sale	168.33	20,000	3,366,604	123,269	Jun 26 04:10 PM
JACK ANDERS	Officer	Jun 24 '26	Proposed Sale	169.51	20,000	3,390,200		Jun 24 04:35 PM
Mancini Anthony	See Remarks	Jun 16 '26	Sale	156.12	4,615	720,490	49,975	Jun 18 04:11 PM
GOLDSMITH MARK A	See Remarks	Jun 16 '26	Sale	156.12	10,020	1,564,310	267,330	Jun 18 04:11 PM
Cislini Jeff	General Counsel	Jun 16 '26	Sale	156.12	2,157	336,749	56,521	Jun 18 04:10 PM
Anders Jack	Chief Financial Officer	Jun 16 '26	Sale	156.12	2,722	424,956	123,269	Jun 18 04:10 PM
Kelsey Stephen Michael	See Remarks	Jun 16 '26	Sale	156.12	4,175	651,798	291,876	Jun 18 04:10 PM
Horn Margaret A	Chief Operating Officer	Jun 15 '26	Option Exercise	32.62	60,400	1,969,993	218,622	Jun 17 07:51 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '26	Option Exercise	27.14	29,600	803,456	184,247	Jun 17 07:51 PM
Horn Margaret A	Chief Operating Officer	Jun 15 '26	Sale	160.17	60,400	9,674,304	158,222	Jun 17 07:51 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '26	Sale	160.12	29,600	4,739,679	154,647	Jun 17 07:51 PM
GOLDSMITH MARK A	Officer	Jun 15 '26	Proposed Sale	153.87	9,772	1,503,618		Jun 15 06:30 PM
Cislini Jeff	Officer	Jun 15 '26	Proposed Sale	153.87	1,656	254,809		Jun 15 06:23 PM
Anders Jack	Officer	Jun 15 '26	Proposed Sale	153.87	2,653	408,217		Jun 15 06:15 PM
Mancini Anthony	Officer	Jun 15 '26	Proposed Sale	153.87	4,211	647,947		Jun 15 06:07 PM
Kelsey Stephen Michael	Officer	Jun 15 '26	Proposed Sale	153.87	4,071	626,405		Jun 15 05:59 PM
Horn Margaret A	Officer	Jun 15 '26	Proposed Sale	153.87	3,486	536,391		Jun 15 05:51 PM
MARGARET A HORN	Officer	Jun 15 '26	Proposed Sale	153.87	90,000	13,848,300		Jun 15 04:59 PM
Horn Margaret A	Chief Operating Officer	Jun 11 '26	Option Exercise	40.93	10,000	409,271	168,222	Jun 15 04:05 PM
Horn Margaret A	Chief Operating Officer	Jun 11 '26	Sale	148.01	10,000	1,480,139	158,222	Jun 15 04:05 PM
MARGARET A HORN	Officer	Jun 11 '26	Proposed Sale	144.19	10,000	1,441,900		Jun 11 04:28 PM
Mancini Anthony	See Remarks	May 26 '26	Option Exercise	33.62	3,121	104,928	57,521	May 28 04:10 PM
Mancini Anthony	See Remarks	May 26 '26	Sale	153.99	3,121	480,611	54,400	May 28 04:10 PM
ANTHONY MANCINI	Officer	May 26 '26	Proposed Sale	151.56	3,121	473,019		May 26 04:46 PM
Mancini Anthony	See Remarks	Apr 27 '26	Option Exercise	33.62	3,120	104,894	57,520	Apr 29 05:50 PM
Mancini Anthony	See Remarks	Apr 27 '26	Sale	132.41	3,120	413,129	54,400	Apr 29 05:50 PM
ANTHONY MANCINI	Officer	Apr 27 '26	Proposed Sale	135.30	3,120	422,136		Apr 27 04:32 PM
GOLDSMITH MARK A	See Remarks	Apr 15 '26	Option Exercise	4.61	120,000	552,724	396,698	Apr 17 07:26 PM
GOLDSMITH MARK A	See Remarks	Apr 15 '26	Sale	150.09	120,000	18,010,488	276,698	Apr 17 07:26 PM
MARK A GOLDSMITH	Director	Apr 15 '26	Proposed Sale	147.01	120,000	17,641,200		Apr 15 04:53 PM
Mancini Anthony	See Remarks	Mar 25 '26	Option Exercise	33.62	37,450	1,259,069	91,850	Mar 26 08:04 PM
Mancini Anthony	See Remarks	Mar 25 '26	Sale	95.56	37,450	3,578,821	54,400	Mar 26 08:04 PM
Mancini Anthony	Officer	Mar 25 '26	Proposed Sale	95.56	37,450	3,578,823		Mar 26 08:01 PM
Wei Lin	Chief Medical Officer	Mar 17 '26	Sale	99.48	2,073	206,223	101,366	Mar 19 06:57 PM
Kelsey Stephen Michael	See Remarks	Mar 17 '26	Sale	99.48	4,302	427,965	295,398	Mar 19 06:57 PM
GOLDSMITH MARK A	See Remarks	Mar 17 '26	Sale	99.48	12,871	1,280,412	276,698	Mar 19 06:56 PM
Horn Margaret A	Chief Operating Officer	Mar 17 '26	Sale	99.48	4,583	455,919	157,570	Mar 19 06:56 PM
Anders Jack	Chief Financial Officer	Mar 17 '26	Sale	99.48	2,753	273,870	125,512	Mar 19 06:55 PM
Cislini Jeff	General Counsel	Mar 17 '26	Sale	99.48	1,795	178,567	59,681	Mar 19 06:54 PM
Cislini Jeff	General Counsel	Mar 19 '26	Sale	97.44	1,163	113,323	58,518	Mar 19 06:54 PM
Wang Xiaolin	See Remarks	Mar 17 '26	Sale	99.48	2,010	199,956	116,063	Mar 19 06:53 PM
JEFFREY TODD CISLINI	Officer	Mar 19 '26	Proposed Sale	98.11	1,163	114,102		Mar 19 04:22 PM
Wang Xiaolin	Officer	Mar 16 '26	Proposed Sale	99.59	2,282	227,264		Mar 13 07:41 PM
Wei Lin	Officer	Mar 16 '26	Proposed Sale	99.59	2,288	227,862		Mar 13 07:40 PM
Kelsey Stephen Michael	Officer	Mar 16 '26	Proposed Sale	99.59	3,901	388,501		Mar 13 07:38 PM
Horn Margaret A	Officer	Mar 16 '26	Proposed Sale	99.59	4,722	470,264		Mar 13 07:36 PM
GOLDSMITH MARK A	Officer	Mar 16 '26	Proposed Sale	99.59	13,261	1,320,663		Mar 13 07:34 PM
Cislini Jeff	Officer	Mar 16 '26	Proposed Sale	99.59	2,053	204,458		Mar 13 07:31 PM
Anders Jack	Officer	Mar 16 '26	Proposed Sale	99.59	2,134	212,525		Mar 13 07:24 PM
GOLDSMITH MARK A	See Remarks	Mar 02 '26	Option Exercise	4.09	30,000	122,700	319,569	Mar 03 09:09 PM
GOLDSMITH MARK A	See Remarks	Mar 02 '26	Sale	101.22	30,000	3,036,576	289,569	Mar 03 09:09 PM
GOLDSMITH MARK A	See Remarks	Mar 02 '26	Sale	101.30	6,000	607,778	64,424	Mar 03 09:09 PM
JONATHAN GOLDSMITH REVOCABLE T	Director	Mar 02 '26	Proposed Sale	102.02	3,000	306,060		Mar 02 04:33 PM
THE REBECCA GOLDSMITH REVOCABL	Director	Mar 02 '26	Proposed Sale	102.02	3,000	306,060		Mar 02 04:33 PM
MARK A GOLDSMITH	Director	Mar 02 '26	Proposed Sale	102.02	30,000	3,060,600		Mar 02 04:32 PM
GOLDSMITH MARK A	See Remarks	Feb 06 '26	Option Exercise	0.54	24,010	12,965	256,479	Feb 10 05:30 PM
Cislini Jeff	General Counsel	Jan 21 '26	Sale	115.60	908	104,965	46,976	Jan 23 04:31 PM
JEFFREY TODD CISLINI	Officer	Jan 21 '26	Proposed Sale	116.22	908	105,528		Jan 21 04:23 PM
Horn Margaret A	Chief Operating Officer	Jan 07 '26	Option Exercise	38.47	75,000	2,885,286	216,053	Jan 09 04:20 PM
Horn Margaret A	Chief Operating Officer	Jan 07 '26	Sale	100.56	75,000	7,542,023	141,053	Jan 09 04:20 PM
Anders Jack	Chief Financial Officer	Jan 07 '26	Option Exercise	42.45	10,000	424,500	118,065	Jan 09 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVMD

Revolution Medicines Inc

Upgrade your Finviz experience